earnings news from FiercePharma
News
AZ stock leaps on Seroquel hearing news
Color AstraZeneca hopeful. A U.S. court hearing over Seroquel's patents has been bumped forward to today from June 4, boosting speculation that the drugmaker might just come out on top in the
Read more...FDA nixes Merck, Schering allergy combo
In another blow to the Merck/Schering-Plough joint venture, the FDA rejected a proposed allergy and asthma treatment that would have Read more...
As former exec indicted, BMS posts growth
A triad of Bristol-Myers Squibb news today, some good, some not-so-good. First, let's get the earnings out of the way: The company reported a decline in earnings on restructuring charges, but Read more...
GSK, Schering-Plough profits drop
When big drugs tank, they take their makers down with them. Witness first-quarter reports from GlaxoSmithKline and Schering-Plough. GSK is suffering on a Read more...
Vytorin news buried in Merck report
Read deep into Merck's first-quarter earnings report and you'll find some Vytorin secrets spilled. First off, the company expects to lose some $700 million in revenues off the blockbuster Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends